[
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company 2025 Q4 - Results - Earnings Call Presentation",
    "summary": "2026-02-05. The following slide deck was published by Bristol-Myers Squibb Company in conjunction with their 2025 Q4 earnings call.",
    "url": "https://finnhub.io/api/news?id=7c046184acd218d84c6f6dda1589332168d46a2ebf96472984496a441a872bb2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770334238,
      "headline": "Bristol-Myers Squibb Company 2025 Q4 - Results - Earnings Call Presentation",
      "id": 138371400,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "2026-02-05. The following slide deck was published by Bristol-Myers Squibb Company in conjunction with their 2025 Q4 earnings call.",
      "url": "https://finnhub.io/api/news?id=7c046184acd218d84c6f6dda1589332168d46a2ebf96472984496a441a872bb2"
    }
  },
  {
    "ts": null,
    "headline": "Why Bristol Myers Squibb Stock Topped the Market Today",
    "summary": "At the end of last year, the company did particularly well with its lineup of newer medications.",
    "url": "https://finnhub.io/api/news?id=c458648613d437eed91ff3ecd1e0db654ca70e82cf508b5d73c152abaaa38c10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770330700,
      "headline": "Why Bristol Myers Squibb Stock Topped the Market Today",
      "id": 138369853,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "At the end of last year, the company did particularly well with its lineup of newer medications.",
      "url": "https://finnhub.io/api/news?id=c458648613d437eed91ff3ecd1e0db654ca70e82cf508b5d73c152abaaa38c10"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Expands RNA And Cell Therapy Pipeline As Valuation Lags",
    "summary": "Bristol-Myers Squibb (NYSE:BMY) is acquiring Orbital Therapeutics in a $1.5b deal to expand its next generation RNA therapy capabilities. The company has entered a new commercial manufacturing agreement for its CAR T cell therapy programmes. Bristol-Myers Squibb also signed a new collaboration and license agreement with Janux Therapeutics focused on a solid tumor therapy. For investors watching NYSE:BMY at a share price of $57.62, these deals come as the company looks to refresh its...",
    "url": "https://finnhub.io/api/news?id=4ceebfed8e5c844e527146755b29614ea048977aa85c3c921de7235517a85a14",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770322203,
      "headline": "Bristol Myers Squibb Expands RNA And Cell Therapy Pipeline As Valuation Lags",
      "id": 138368797,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb (NYSE:BMY) is acquiring Orbital Therapeutics in a $1.5b deal to expand its next generation RNA therapy capabilities. The company has entered a new commercial manufacturing agreement for its CAR T cell therapy programmes. Bristol-Myers Squibb also signed a new collaboration and license agreement with Janux Therapeutics focused on a solid tumor therapy. For investors watching NYSE:BMY at a share price of $57.62, these deals come as the company looks to refresh its...",
      "url": "https://finnhub.io/api/news?id=4ceebfed8e5c844e527146755b29614ea048977aa85c3c921de7235517a85a14"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Co (BMY) Q4 2025 Earnings Call Highlights: Strong Growth in New Products ...",
    "summary": "Bristol-Myers Squibb Co (BMY) reports robust growth in its new product portfolio while navigating revenue declines in its legacy offerings.",
    "url": "https://finnhub.io/api/news?id=b624a5cd703aeec37d5a1b20f42233f04473033fa2a0d18c9184ae154f0d649e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770318249,
      "headline": "Bristol-Myers Squibb Co (BMY) Q4 2025 Earnings Call Highlights: Strong Growth in New Products ...",
      "id": 138367598,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Co (BMY) reports robust growth in its new product portfolio while navigating revenue declines in its legacy offerings.",
      "url": "https://finnhub.io/api/news?id=b624a5cd703aeec37d5a1b20f42233f04473033fa2a0d18c9184ae154f0d649e"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Earnings Reveal Struggling Legacy Drug Business. Why the Stock Is Rising.",
    "summary": "Bristol Myers Squibb issues an especially upbeat outlook for 2026, even as revenue is expected to fall within one product portfolio.",
    "url": "https://finnhub.io/api/news?id=e023ba7adf30612f58aff2384b5aca279f281f7299d45492b80c82e255d58123",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770316140,
      "headline": "Bristol Myers Earnings Reveal Struggling Legacy Drug Business. Why the Stock Is Rising.",
      "id": 138367495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb issues an especially upbeat outlook for 2026, even as revenue is expected to fall within one product portfolio.",
      "url": "https://finnhub.io/api/news?id=e023ba7adf30612f58aff2384b5aca279f281f7299d45492b80c82e255d58123"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY) Q4 2025 Earnings Call Transcript",
    "summary": "Bristol-Myers Squibb Company (BMY) Q4 2025 Earnings Call February 5, 2026 8:00 AM ESTCompany ParticipantsCharles Triano - SVP & Head of Investor...",
    "url": "https://finnhub.io/api/news?id=92d4617e8c2374627c57e7cc524fbe507a9007d53d81000d1cc5409877ba97d8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770314659,
      "headline": "Bristol-Myers Squibb Company (BMY) Q4 2025 Earnings Call Transcript",
      "id": 138369425,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb Company (BMY) Q4 2025 Earnings Call February 5, 2026 8:00 AM ESTCompany ParticipantsCharles Triano - SVP & Head of Investor...",
      "url": "https://finnhub.io/api/news?id=92d4617e8c2374627c57e7cc524fbe507a9007d53d81000d1cc5409877ba97d8"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Expects Sales To Decline This Year; So Why Is The Stock Rising?",
    "summary": "Bristol Myers Squibb stock rose moderately Thursday on better-than-expected fourth-quarter metrics and a strong 2026 outlook.",
    "url": "https://finnhub.io/api/news?id=6f647a8dd418409d8eb9213c7e791aef29162d9e680df8cc2cddcacd2149d29c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770311505,
      "headline": "Bristol Myers Expects Sales To Decline This Year; So Why Is The Stock Rising?",
      "id": 138366226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb stock rose moderately Thursday on better-than-expected fourth-quarter metrics and a strong 2026 outlook.",
      "url": "https://finnhub.io/api/news?id=6f647a8dd418409d8eb9213c7e791aef29162d9e680df8cc2cddcacd2149d29c"
    }
  },
  {
    "ts": null,
    "headline": "Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myers’ waiting game",
    "summary": "Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie franchise and Bristol Myers pointed to a trio of narrative-changing trials.",
    "url": "https://finnhub.io/api/news?id=45bf1f51a16434d720f80c7fb6d1f0bb4c047c54b4d6ef26bc4597375ef87d3e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770309120,
      "headline": "Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myers’ waiting game",
      "id": 138368710,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie franchise and Bristol Myers pointed to a trio of narrative-changing trials.",
      "url": "https://finnhub.io/api/news?id=45bf1f51a16434d720f80c7fb6d1f0bb4c047c54b4d6ef26bc4597375ef87d3e"
    }
  },
  {
    "ts": null,
    "headline": "Weekly Jobless Claims Exceed Expectations",
    "summary": "Weekly Jobless Claims Exceed Expectations.",
    "url": "https://finnhub.io/api/news?id=281101f8fddd2530cba3c1b2e88478d35772bf1fc2aac145f69b790aa50ffe37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770307680,
      "headline": "Weekly Jobless Claims Exceed Expectations",
      "id": 138366227,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Weekly Jobless Claims Exceed Expectations.",
      "url": "https://finnhub.io/api/news?id=281101f8fddd2530cba3c1b2e88478d35772bf1fc2aac145f69b790aa50ffe37"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn’t Even Hit Yet",
    "summary": "Bristol Myers Squibb (NYSE:BMY) reported Q4 2025 revenue of $12.5 billion, essentially flat year-over-year, with full-year 2025 revenue reaching $48.2 billion. The pharmaceutical giant delivered non-GAAP EPS of $1.26 for the quarter, which included a $(0.60) impact from Orbital Therapeutics acquisition charges. The company announced results on Thursday, February 5, 2026, before market open. Growth ... Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn’t Even Hit Yet",
    "url": "https://finnhub.io/api/news?id=e4f51ce83625f11b4d5f8055b044493986b027fd25f96dd09061276b1570a02f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770306648,
      "headline": "Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn’t Even Hit Yet",
      "id": 138366228,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb (NYSE:BMY) reported Q4 2025 revenue of $12.5 billion, essentially flat year-over-year, with full-year 2025 revenue reaching $48.2 billion. The pharmaceutical giant delivered non-GAAP EPS of $1.26 for the quarter, which included a $(0.60) impact from Orbital Therapeutics acquisition charges. The company announced results on Thursday, February 5, 2026, before market open. Growth ... Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn’t Even Hit Yet",
      "url": "https://finnhub.io/api/news?id=e4f51ce83625f11b4d5f8055b044493986b027fd25f96dd09061276b1570a02f"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates",
    "summary": "BMY beats Q4 earnings and revenue estimates as its Growth Portfolio jumps 16%, lifting shares despite continued declines in legacy drugs.",
    "url": "https://finnhub.io/api/news?id=e46a0ab21327ed6bb39156280d1c0445c43861872015ece9381525be3e2b1a49",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770306540,
      "headline": "Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates",
      "id": 138366188,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMY beats Q4 earnings and revenue estimates as its Growth Portfolio jumps 16%, lifting shares despite continued declines in legacy drugs.",
      "url": "https://finnhub.io/api/news?id=e46a0ab21327ed6bb39156280d1c0445c43861872015ece9381525be3e2b1a49"
    }
  },
  {
    "ts": null,
    "headline": "Jobless Claims Pop Up a Bit, Major Morning for Earnings",
    "summary": "Jobless Claims notched their highest weekly print since early December, while BMY, RL, COP & more report earnings.",
    "url": "https://finnhub.io/api/news?id=709ca9fe735c3a53a0241d5e0ed6c5a110df8104b6b5c46f6e5dbea83831946f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770305520,
      "headline": "Jobless Claims Pop Up a Bit, Major Morning for Earnings",
      "id": 138366208,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Jobless Claims notched their highest weekly print since early December, while BMY, RL, COP & more report earnings.",
      "url": "https://finnhub.io/api/news?id=709ca9fe735c3a53a0241d5e0ed6c5a110df8104b6b5c46f6e5dbea83831946f"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Stock Rises on Earnings. This Drug Portfolio Continues to Be a Drag.",
    "summary": "Bristol Myers Squibb issues an especially upbeat outlook for 2026, even as revenue is expected to fall within one product portfolio.",
    "url": "https://finnhub.io/api/news?id=97db74ad7b72973be06edf50945817c5cee783d8b3cbd76b135d1ae7ee095c5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770305100,
      "headline": "Bristol Myers Stock Rises on Earnings. This Drug Portfolio Continues to Be a Drag.",
      "id": 138366087,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb issues an especially upbeat outlook for 2026, even as revenue is expected to fall within one product portfolio.",
      "url": "https://finnhub.io/api/news?id=97db74ad7b72973be06edf50945817c5cee783d8b3cbd76b135d1ae7ee095c5b"
    }
  },
  {
    "ts": null,
    "headline": "White House launches direct-to-consumer drug site TrumpRx. Here's what to know",
    "summary": "It's still unclear if all patients, particularly those with insurance coverage, will see more cost savings from using that site to buy their medicines.",
    "url": "https://finnhub.io/api/news?id=2bd365464a64554c833510a14890e7731969ce8b179362b23305539a1ee9b7eb",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770305054,
      "headline": "White House launches direct-to-consumer drug site TrumpRx. Here's what to know",
      "id": 138376237,
      "image": "https://image.cnbcfm.com/api/v1/image/108262460-1770383887859-gettyimages-2259525568-TRUMPRX_LAUNCH.jpeg?v=1770384067&w=1920&h=1080",
      "related": "BMY",
      "source": "CNBC",
      "summary": "It's still unclear if all patients, particularly those with insurance coverage, will see more cost savings from using that site to buy their medicines. ",
      "url": "https://finnhub.io/api/news?id=2bd365464a64554c833510a14890e7731969ce8b179362b23305539a1ee9b7eb"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb CEO: Richest product pipeline we've had in the last decade",
    "summary": "Chris Boerner, Bristol Myers Squibb CEO, joins CNBC's \"Power Lunch\" to discuss the company's quarterly earnings results, the drug pipeline and much more.",
    "url": "https://finnhub.io/api/news?id=afedf65c0abf8c2bd1ef6e31a941956443b952aad488b82ed729b6512e0ec298",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770303531,
      "headline": "Bristol Myers Squibb CEO: Richest product pipeline we've had in the last decade",
      "id": 138376347,
      "image": "https://image.cnbcfm.com/api/v1/image/108262158-1770330297389-thumb1.jpg?v=1770330307&w=1920&h=1080",
      "related": "BMY",
      "source": "CNBC",
      "summary": "Chris Boerner, Bristol Myers Squibb CEO, joins CNBC's \"Power Lunch\" to discuss the company's quarterly earnings results, the drug pipeline and much more.",
      "url": "https://finnhub.io/api/news?id=afedf65c0abf8c2bd1ef6e31a941956443b952aad488b82ed729b6512e0ec298"
    }
  },
  {
    "ts": null,
    "headline": "This Medical Technology Leader Sees Growth Into The 2040s",
    "summary": "Medical technology leader Halozyme Therapeutics is this week's IBD Sector Leaders selection, having bypassed two buy points and entered a buy zone. The recent IBD Stock Of The Day is rallying after the company raised its 2025 and 2026 outlook.",
    "url": "https://finnhub.io/api/news?id=465458d7404af0b7fba7176e60fd2dabe65f7c5503d605c1316f76310d768b75",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770303347,
      "headline": "This Medical Technology Leader Sees Growth Into The 2040s",
      "id": 138364445,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Medical technology leader Halozyme Therapeutics is this week's IBD Sector Leaders selection, having bypassed two buy points and entered a buy zone. The recent IBD Stock Of The Day is rallying after the company raised its 2025 and 2026 outlook.",
      "url": "https://finnhub.io/api/news?id=465458d7404af0b7fba7176e60fd2dabe65f7c5503d605c1316f76310d768b75"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers (BMY) Q4 2025 Earnings Transcript",
    "summary": "Chuck Triano: Thank you and good morning everyone.  With me this morning with prepared remarks are Christopher Boerner, our board chair and chief executive officer, and David Elkins, our chief financial officer.  Also participating in today's call is Adam Lenkowsky, our chief commercialization officer, and Cristian Massacesi, our chief medical officer and head of global drug development.",
    "url": "https://finnhub.io/api/news?id=90973b2ce2ff5530db89a2e2c1e102525f571eece1f2bcfc8674189283bd0aa5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770302724,
      "headline": "Bristol Myers (BMY) Q4 2025 Earnings Transcript",
      "id": 138364581,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Chuck Triano: Thank you and good morning everyone.  With me this morning with prepared remarks are Christopher Boerner, our board chair and chief executive officer, and David Elkins, our chief financial officer.  Also participating in today's call is Adam Lenkowsky, our chief commercialization officer, and Cristian Massacesi, our chief medical officer and head of global drug development.",
      "url": "https://finnhub.io/api/news?id=90973b2ce2ff5530db89a2e2c1e102525f571eece1f2bcfc8674189283bd0aa5"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers (BMY) Reports Q4 Earnings: What Key Metrics Have to Say",
    "summary": "Although the revenue and EPS for Bristol Myers (BMY) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
    "url": "https://finnhub.io/api/news?id=0ed69572a00169f2ab373a9e1f731fd0baff8961190aa04a277b3a4b0a35ee31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770301805,
      "headline": "Bristol Myers (BMY) Reports Q4 Earnings: What Key Metrics Have to Say",
      "id": 138364582,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Although the revenue and EPS for Bristol Myers (BMY) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
      "url": "https://finnhub.io/api/news?id=0ed69572a00169f2ab373a9e1f731fd0baff8961190aa04a277b3a4b0a35ee31"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Rises Inside A Buy Zone On Street-Beating 2026 Outlook",
    "summary": "Bristol Myers Squibb stock rose moderately Thursday on better-than-expected fourth-quarter metrics and a strong 2026 outlook.",
    "url": "https://finnhub.io/api/news?id=46e82a818366b0780edf0ad8814839ed66d26fcceb8d0e8ec9cb3b368b565b5a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770299469,
      "headline": "Bristol Myers Rises Inside A Buy Zone On Street-Beating 2026 Outlook",
      "id": 138363624,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb stock rose moderately Thursday on better-than-expected fourth-quarter metrics and a strong 2026 outlook.",
      "url": "https://finnhub.io/api/news?id=46e82a818366b0780edf0ad8814839ed66d26fcceb8d0e8ec9cb3b368b565b5a"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q4 CY2025",
    "summary": "Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q4 CY2025, with sales up 1.4% year on year to $12.5 billion. The company’s full-year revenue guidance of $46.75 billion at the midpoint came in 5.7% above analysts’ estimates. Its non-GAAP profit of $1.26 per share was 4.6% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=85d1ef8fc29ce699ee3ff8189ff0ac432fa1f66e8ca0e192be39ab55c4a3946d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770297267,
      "headline": "Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q4 CY2025",
      "id": 138363625,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q4 CY2025, with sales up 1.4% year on year to $12.5 billion. The company’s full-year revenue guidance of $46.75 billion at the midpoint came in 5.7% above analysts’ estimates. Its non-GAAP profit of $1.26 per share was 4.6% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=85d1ef8fc29ce699ee3ff8189ff0ac432fa1f66e8ca0e192be39ab55c4a3946d"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb (BMY) Tops Q4 Earnings and Revenue Estimates",
    "summary": "Bristol Myers (BMY) delivered earnings and revenue surprises of +9.33% and +2.03%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=99d8511da4ccf202c0c1d671e8503e2d055d31548d2b418772fe010aec7f1b05",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770297001,
      "headline": "Bristol Myers Squibb (BMY) Tops Q4 Earnings and Revenue Estimates",
      "id": 138364583,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers (BMY) delivered earnings and revenue surprises of +9.33% and +2.03%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=99d8511da4ccf202c0c1d671e8503e2d055d31548d2b418772fe010aec7f1b05"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Stock Rises. Why Fourth-Quarter Earnings Are Exciting Investors.",
    "summary": "Bristol Myers Squibb  rose Thursday on the back of better-than-expected fourth-quarter earnings but most encouraging was an upbeat outlook from the drugmaker.  Bristol Myers  reported adjusted earnings of $1.26 a share, topping analysts’ consensus of $1.23.  For 2026,  Bristol Myers  sees adjusted earnings in the range of $6.05 to $6.35 a share, above analysts’ forecasts for $6.02.",
    "url": "https://finnhub.io/api/news?id=ecf06dd14e57d1c01f61f55d8b25549a48ac9a3088e15b107b08a4ab20045ece",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770297000,
      "headline": "Bristol Myers Stock Rises. Why Fourth-Quarter Earnings Are Exciting Investors.",
      "id": 138363626,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb  rose Thursday on the back of better-than-expected fourth-quarter earnings but most encouraging was an upbeat outlook from the drugmaker.  Bristol Myers  reported adjusted earnings of $1.26 a share, topping analysts’ consensus of $1.23.  For 2026,  Bristol Myers  sees adjusted earnings in the range of $6.05 to $6.35 a share, above analysts’ forecasts for $6.02.",
      "url": "https://finnhub.io/api/news?id=ecf06dd14e57d1c01f61f55d8b25549a48ac9a3088e15b107b08a4ab20045ece"
    }
  },
  {
    "ts": null,
    "headline": "Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals",
    "summary": "This report provides an in-depth analysis of the Cell and Gene Therapy industry, highlighting key company revenues, regulatory approvals, and market trends. It has been compiled by Towards Healthcare, a sister firm of Precedence Research, offering valuable insights into the latest developments and financials in this rapidly advancing field.Ottawa, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cell and gene therapy (CGT) is rapidly advancing, with major players like Novartis, Gilead, and Bristol Myers Squibb",
    "url": "https://finnhub.io/api/news?id=7bd9f5e4b72b285309a575d0a27b7eb36934c64bb574d9a45dbb8f7700692882",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770296400,
      "headline": "Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals",
      "id": 138363586,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "This report provides an in-depth analysis of the Cell and Gene Therapy industry, highlighting key company revenues, regulatory approvals, and market trends. It has been compiled by Towards Healthcare, a sister firm of Precedence Research, offering valuable insights into the latest developments and financials in this rapidly advancing field.Ottawa, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cell and gene therapy (CGT) is rapidly advancing, with major players like Novartis, Gilead, and Bristol Myers Squibb",
      "url": "https://finnhub.io/api/news?id=7bd9f5e4b72b285309a575d0a27b7eb36934c64bb574d9a45dbb8f7700692882"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Today’s Movers: Alphabet, Qualcomm, Broadcom, AMD, Nvidia, Arm, Align, Amazon, and More",
    "summary": "Google parent Alphabet beats analysts’ expectations for quarterly earnings and revenue but its capital spending forecasts widely top estimates.",
    "url": "https://finnhub.io/api/news?id=97cca46b96917c88f81f5e3d5eb973788779dfbf70eed7054a4114ac675ab917",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770289560,
      "headline": "These Stocks Are Today’s Movers: Alphabet, Qualcomm, Broadcom, AMD, Nvidia, Arm, Align, Amazon, and More",
      "id": 138362602,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Google parent Alphabet beats analysts’ expectations for quarterly earnings and revenue but its capital spending forecasts widely top estimates.",
      "url": "https://finnhub.io/api/news?id=97cca46b96917c88f81f5e3d5eb973788779dfbf70eed7054a4114ac675ab917"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off",
    "summary": "By Michael Erman Feb 5 (Reuters) - Bristol Myers Squibb on Thursday forecast 2026 results above Wall Street estimates, saying that price cuts to its blood thinner Eliquis will help drive up revenue,",
    "url": "https://finnhub.io/api/news?id=e3e3b2587a9c212737f72e36c972c8b6e5d9668341958ca4bfbd58defe5007b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770294621,
      "headline": "Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off",
      "id": 138363629,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "By Michael Erman Feb 5 (Reuters) - Bristol Myers Squibb on Thursday forecast 2026 results above Wall Street estimates, saying that price cuts to its blood thinner Eliquis will help drive up revenue,",
      "url": "https://finnhub.io/api/news?id=e3e3b2587a9c212737f72e36c972c8b6e5d9668341958ca4bfbd58defe5007b5"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers: Q4 Earnings Snapshot",
    "summary": "PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported fourth-quarter net income of $1.09 billion. The Princeton, New Jersey-based company said it had profit of 53 cents per share. Earnings, adjusted for non-recurring costs, came to $1.26 per share.",
    "url": "https://finnhub.io/api/news?id=d3955c2c197543ddd229879c65dbb7120e69651b3422c5cc65da7790f84deecc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770293347,
      "headline": "Bristol Myers: Q4 Earnings Snapshot",
      "id": 138363630,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported fourth-quarter net income of $1.09 billion. The Princeton, New Jersey-based company said it had profit of 53 cents per share. Earnings, adjusted for non-recurring costs, came to $1.26 per share.",
      "url": "https://finnhub.io/api/news?id=d3955c2c197543ddd229879c65dbb7120e69651b3422c5cc65da7790f84deecc"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Revenue Ticks Up on Immuno-Oncology Growth",
    "summary": "Bristol Myers Squibb reported higher fourth-quarter revenue as growth in sales of its immuno-oncology treatments helped to offset a decline in revenue for some of its older drugs.",
    "url": "https://finnhub.io/api/news?id=b3f746f72569090f6dcabcb89341c6cee0fe2860f41b70f0a249a414c215f5be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770293340,
      "headline": "Bristol Myers Squibb Revenue Ticks Up on Immuno-Oncology Growth",
      "id": 138363631,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb reported higher fourth-quarter revenue as growth in sales of its immuno-oncology treatments helped to offset a decline in revenue for some of its older drugs.",
      "url": "https://finnhub.io/api/news?id=b3f746f72569090f6dcabcb89341c6cee0fe2860f41b70f0a249a414c215f5be"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025",
    "summary": "PRINCETON, N.J., February 05, 2026--Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025",
    "url": "https://finnhub.io/api/news?id=6387e7238bf1cb0827cc25cc53eb59f8de9182c5b0cb44fa9bdb94aa73303840",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770292740,
      "headline": "Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025",
      "id": 138363632,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., February 05, 2026--Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025",
      "url": "https://finnhub.io/api/news?id=6387e7238bf1cb0827cc25cc53eb59f8de9182c5b0cb44fa9bdb94aa73303840"
    }
  },
  {
    "ts": null,
    "headline": "Stocks making the biggest moves premarket: Qualcomm, Strategy, Align, Estee Lauder and more",
    "summary": "These are the stocks posting the largest moves in the premarket.",
    "url": "https://finnhub.io/api/news?id=5a6a5245fc85319e3dfbcec3aae3c3fcc9e249f24156a157b02d35d8d880e310",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770277162,
      "headline": "Stocks making the biggest moves premarket: Qualcomm, Strategy, Align, Estee Lauder and more",
      "id": 138365418,
      "image": "https://image.cnbcfm.com/api/v1/image/108249283-1767792520478-gettyimages-2255034963-vcg111613739731.jpeg?v=1767792555&w=1920&h=1080",
      "related": "BMY",
      "source": "CNBC",
      "summary": "These are the stocks posting the largest moves in the premarket.",
      "url": "https://finnhub.io/api/news?id=5a6a5245fc85319e3dfbcec3aae3c3fcc9e249f24156a157b02d35d8d880e310"
    }
  },
  {
    "ts": null,
    "headline": "Amazon earnings, Fed commentary, mortgage rates: What to Watch",
    "summary": "Market Domination Overtime Host Josh Lipton previews several of the biggest stories to come tomorrow, Thursday, February 5, including earnings results from companies like Amazon (AMZN), Strategy (MSTR), Shell (SHEL), and ConocoPhillips (COP); commentary from Federal Reserve Bank of Atlanta President Raphael Bostic; and the latest reading on US mortgage rates. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
    "url": "https://finnhub.io/api/news?id=5d8e397bf88d3e8ef5a3150262ef70a8c90c812e1ad90108e48cd569352337e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770249600,
      "headline": "Amazon earnings, Fed commentary, mortgage rates: What to Watch",
      "id": 138359159,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Market Domination Overtime Host Josh Lipton previews several of the biggest stories to come tomorrow, Thursday, February 5, including earnings results from companies like Amazon (AMZN), Strategy (MSTR), Shell (SHEL), and ConocoPhillips (COP); commentary from Federal Reserve Bank of Atlanta President Raphael Bostic; and the latest reading on US mortgage rates. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
      "url": "https://finnhub.io/api/news?id=5d8e397bf88d3e8ef5a3150262ef70a8c90c812e1ad90108e48cd569352337e4"
    }
  }
]